| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome
|
Ashcraft, Keith A.
|
|
|
38 |
12 |
p. 932.e1-932.e7
|
artikel
|
| 2 |
Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma
|
Beck, W
|
|
|
38 |
12 |
p. 906
|
artikel
|
| 3 |
An evaluation of single-sample tumor subtype classification methods
|
Eriksson, P
|
|
|
38 |
12 |
p. 906-907
|
artikel
|
| 4 |
An exploratory proteomic study delineating the local and systemic immune-oncologic profile of urinary bladder cancer patients
|
Lord, M
|
|
|
38 |
12 |
p. 905-906
|
artikel
|
| 5 |
Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma
|
Laukhtina, Ekaterina
|
|
|
38 |
12 |
p. 936.e7-936.e14
|
artikel
|
| 6 |
Black race may be associated with worse overall survival in renal cell carcinoma patients
|
Anastos, Harry
|
|
|
38 |
12 |
p. 938.e9-938.e17
|
artikel
|
| 7 |
Bladder cancer incidence rates and trends in young adults aged 20-39 years
|
Palumbo, Carlotta
|
|
|
38 |
12 |
p. 934.e11-934.e19
|
artikel
|
| 8 |
Blue light cystoscopy for detection of invasive bladder tumor: Results from multi-institutional registry
|
Ahmadi, H
|
|
|
38 |
12 |
p. 900
|
artikel
|
| 9 |
Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial
|
Marandino, L
|
|
|
38 |
12 |
p. 900
|
artikel
|
| 10 |
CDK4/6 inhibitors improve therapy of oncolytic adenovirus by manipulation of RB-E2F regulated transcription
|
Nawroth, R
|
|
|
38 |
12 |
p. 908-909
|
artikel
|
| 11 |
Common deleterious germline variants shape the urothelial cancer genome
|
Vosoughi, A
|
|
|
38 |
12 |
p. 897
|
artikel
|
| 12 |
Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care
|
Bagheri, I
|
|
|
38 |
12 |
p. 903
|
artikel
|
| 13 |
Continuous Bladder Irrigation after Transurethral Resection of Non-Muscle Invasive Bladder Cancer for Prevention of Tumour Recurrence – A Systematic Review
|
Li, M
|
|
|
38 |
12 |
p. 901
|
artikel
|
| 14 |
Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer
|
Brooks, NA
|
|
|
38 |
12 |
p. 902-903
|
artikel
|
| 15 |
CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer
|
Powles, T
|
|
|
38 |
12 |
p. 911
|
artikel
|
| 16 |
Cytotoxic and genotoxic effects of epigenetic inhibitors on bladder cancer cells
|
Hoffmann, MJ
|
|
|
38 |
12 |
p. 909
|
artikel
|
| 17 |
Development and characterization of a novel autochthonous semi-spontaneous bladder cancer model by pathological evaluation, single cell sequencing and proteomic profiling
|
Kerzeli, IK
|
|
|
38 |
12 |
p. 896
|
artikel
|
| 18 |
Development of a novel nomogram incorporating platelet-to-lymphocyte ratio for the prediction of lymph node involvement in prostate carcinoma
|
Merhe, Ali
|
|
|
38 |
12 |
p. 930.e1-930.e6
|
artikel
|
| 19 |
Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study
|
Elsawy, Amr A.
|
|
|
38 |
12 |
p. 935.e1-935.e8
|
artikel
|
| 20 |
Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events
|
Ando, Ryosuke
|
|
|
38 |
12 |
p. 937.e19-937.e25
|
artikel
|
| 21 |
Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer
|
Weyerer, V
|
|
|
38 |
12 |
p. 908
|
artikel
|
| 22 |
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer
|
Kwon, Daniel H.
|
|
|
38 |
12 |
p. 931.e9-931.e16
|
artikel
|
| 23 |
Drug repurposing of bladder cancer driven by patients’ proteomic signatures
|
Mokou, M
|
|
|
38 |
12 |
p. 897-898
|
artikel
|
| 24 |
Early Experience with Intravesical Gemcitabine-Docetaxel for BCG-Naïve Patients with High Grade Non-Muscle Invasive Bladder Cancer
|
Babajide, R
|
|
|
38 |
12 |
p. 901
|
artikel
|
| 25 |
Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1
|
Black, Peter C.
|
|
|
38 |
12 |
p. 855-857
|
artikel
|
| 26 |
Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study
|
Cui, Yan
|
|
|
38 |
12 |
p. 936.e1-936.e6
|
artikel
|
| 27 |
Efficacy of Urinary Mast Cell Activation Markers in Patients with Primary High-Grade Non-Muscle Invasive Bladder Cancer Treated with BCG Immunotherapy
|
Simsekoglu, MF
|
|
|
38 |
12 |
p. 902
|
artikel
|
| 28 |
Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma In-situ is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer
|
Hahn, NM
|
|
|
38 |
12 |
p. 896-897
|
artikel
|
| 29 |
FBXW7 loss of function contributes to worse overall survival and is associated with accumulation of MYC in muscle invasive bladder cancer
|
Matumoto, T
|
|
|
38 |
12 |
p. 904-905
|
artikel
|
| 30 |
Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis
|
Yanagisawa, Takafumi
|
|
|
38 |
12 |
p. 938.e1-938.e7
|
artikel
|
| 31 |
Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer
|
Kumar, G
|
|
|
38 |
12 |
p. 905
|
artikel
|
| 32 |
Genomic and Transcriptomic Characterization of Metastatic Urothelial Carcinoma
|
Nakauma, A
|
|
|
38 |
12 |
p. 910
|
artikel
|
| 33 |
Geographic Distribution of Racial Differences in Bladder Cancer Mortality in the United States: A Nationwide Population-Based Study
|
Freudenburg, E
|
|
|
38 |
12 |
p. 903-904
|
artikel
|
| 34 |
Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders
|
Weyerer, V
|
|
|
38 |
12 |
p. 907
|
artikel
|
| 35 |
Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer
|
Ripping, Theodora M.
|
|
|
38 |
12 |
p. 935.e9-935.e16
|
artikel
|
| 36 |
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival
|
Grunewald, Camilla M.
|
|
|
38 |
12 |
p. 934.e1-934.e9
|
artikel
|
| 37 |
Impact of UTUC on Outcomes of Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin
|
Bree, KK
|
|
|
38 |
12 |
p. 898
|
artikel
|
| 38 |
Investigating sexual dimorphism in the tumour immune microenvironment of non-muscle invasive bladder cancer
|
Chenard, S
|
|
|
38 |
12 |
p. 908
|
artikel
|
| 39 |
Long-Term Outcomes and Costs Among BCG-treated High-Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting
|
Williams, SB
|
|
|
38 |
12 |
p. 902
|
artikel
|
| 40 |
Lytic Effects of Water on Bladder Cancer Cell Lines – Implications for Clinical Use of Water Irrigation to Reduce Recurrence
|
Nandurkar, R
|
|
|
38 |
12 |
p. 901
|
artikel
|
| 41 |
Measurable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease in Patients with High-Grade Non-Muscle Invasive Bladder Cancer
|
Nykopp, TK
|
|
|
38 |
12 |
p. 902
|
artikel
|
| 42 |
Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis
|
Taber, A
|
|
|
38 |
12 |
p. 899
|
artikel
|
| 43 |
Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new seguential therapies in pathologically-nonresponders
|
Necchi, A
|
|
|
38 |
12 |
p. 898-899
|
artikel
|
| 44 |
Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
|
Necchi, A
|
|
|
38 |
12 |
p. 907
|
artikel
|
| 45 |
Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer
|
Hatogai, K
|
|
|
38 |
12 |
p. 907-908
|
artikel
|
| 46 |
Mutational signature modelling in vitro recapitulates bladder cancer initiation
|
Baker, SC
|
|
|
38 |
12 |
p. 909
|
artikel
|
| 47 |
New horizons in bladder cancer research
|
Boormans, Joost L.
|
|
|
38 |
12 |
p. 867-885
|
artikel
|
| 48 |
Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study
|
Matsumoto, Ryuji
|
|
|
38 |
12 |
p. 933.e13-933.e18
|
artikel
|
| 49 |
Organotypic & in vitro monolayer modeling of urothelial carcinoma gives different cellular responses to proteinase activated receptor (PAR) agonism/antagonism
|
de Lima, SG
|
|
|
38 |
12 |
p. 910
|
artikel
|
| 50 |
Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling
|
Luzzago, Stefano
|
|
|
38 |
12 |
p. 929.e11-929.e19
|
artikel
|
| 51 |
Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma
|
Singla, Nirmish
|
|
|
38 |
12 |
p. 933.e7-933.e12
|
artikel
|
| 52 |
Postoperative membranous urethral length is the single most important surgical factor predicting recovery of postoperative urinary continence
|
Cho, Dae Sung
|
|
|
38 |
12 |
p. 930.e7-930.e12
|
artikel
|
| 53 |
Post-translational modifications in bladder cancer: Expanding the tumor target repertoire
|
Oo, Htoo Zarni
|
|
|
38 |
12 |
p. 858-866
|
artikel
|
| 54 |
Predictive and Prognostic Performance of IHC3 Immunohistochemistry-based Molecular Subtyping in Muscle-Invasive Bladder Cancer
|
Hardy, C
|
|
|
38 |
12 |
p. 906
|
artikel
|
| 55 |
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer
|
Freedland, Stephen J.
|
|
|
38 |
12 |
p. 930.e13-930.e21
|
artikel
|
| 56 |
Prognostic impact of somatostatin receptor expression in advanced bladder cancer
|
Maas, Moritz
|
|
|
38 |
12 |
p. 935.e17-935.e28
|
artikel
|
| 57 |
Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy
|
Holz, Serge
|
|
|
38 |
12 |
p. 937.e1-937.e9
|
artikel
|
| 58 |
Radiosensitisation of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota
|
Then, CK
|
|
|
38 |
12 |
p. 910
|
artikel
|
| 59 |
Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes
|
Huelster, Heather L.
|
|
|
38 |
12 |
p. 930.e23-930.e32
|
artikel
|
| 60 |
RBM10: The role of a splicing factor in urothelial homeostasis and tumorigenesis.
|
Maldonado, AM
|
|
|
38 |
12 |
p. 905
|
artikel
|
| 61 |
Recent scenario of long non-coding RNAs as a diagnostic and prognostic biomarkers of prostate cancer
|
Shukla, Kamla Kant
|
|
|
38 |
12 |
p. 918-928
|
artikel
|
| 62 |
Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer
|
Singh, AK
|
|
|
38 |
12 |
p. 899
|
artikel
|
| 63 |
Recurring urothelial carcinomas are clonal but incompatible with a direct relationship
|
Marzouka, N
|
|
|
38 |
12 |
p. 899-900
|
artikel
|
| 64 |
Regulation of PPARγ expression in luminal muscle invasive bladder cancer
|
Tortora, D
|
|
|
38 |
12 |
p. 905
|
artikel
|
| 65 |
Restaging Transurethral Resection of HG Ta Bladder Tumors: A Risk-Adapted Approach
|
Hensley, PJ
|
|
|
38 |
12 |
p. 900-901
|
artikel
|
| 66 |
Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14
|
Rentsch, Cyrill A
|
|
|
38 |
12 |
p. 898
|
artikel
|
| 67 |
Role of CA 125, CA19-9 and CEA in predicting outcome following neoadjuvant chemotherapy in muscle invasive bladder cancer
|
Ahmadi, H
|
|
|
38 |
12 |
p. 903
|
artikel
|
| 68 |
Specific genetic susceptibility patterns of the urothelial bladder cancer taxonomic subtypes
|
Benítez, R
|
|
|
38 |
12 |
p. 897
|
artikel
|
| 69 |
STAG2 and PPARg as drivers of luminal-type bladder cancer
|
Lapi, E
|
|
|
38 |
12 |
p. 896
|
artikel
|
| 70 |
The cost of obesity in radical cystectomy
|
Huynh, Melissa J.
|
|
|
38 |
12 |
p. 932.e9-932.e14
|
artikel
|
| 71 |
The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome
|
Sharma, Meenal
|
|
|
38 |
12 |
p. 933.e1-933.e6
|
artikel
|
| 72 |
The potential for designing urothelial carcinomas using pluripotent stem cell-based systems
|
Melzer, MK
|
|
|
38 |
12 |
p. 909
|
artikel
|
| 73 |
The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
|
Ieiri, Kosuke
|
|
|
38 |
12 |
p. 931.e1-931.e7
|
artikel
|
| 74 |
The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?
|
Asi, Tariq
|
|
|
38 |
12 |
p. 937.e11-937.e17
|
artikel
|
| 75 |
Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*
|
Benderska-Söder, Natalya
|
|
|
38 |
12 |
p. 886-895
|
artikel
|
| 76 |
Transition of ANXA10 expression is a useful diagnostic and prognostic marker in upper tract urothelial carcinoma
|
Hayashi, T
|
|
|
38 |
12 |
p. 904
|
artikel
|
| 77 |
Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists
|
Rosenzweig, Barak
|
|
|
38 |
12 |
p. 929.e1-929.e10
|
artikel
|
| 78 |
Tumor Immune Microenvironment in Response to Radiotherapy vs BCG in a Murine Model of Bladder Cancer
|
Lombardo, K
|
|
|
38 |
12 |
p. 911
|
artikel
|
| 79 |
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer
|
Higano, Celestia S.
|
|
|
38 |
12 |
p. 912-917
|
artikel
|
| 80 |
Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States
|
Jazzar, U
|
|
|
38 |
12 |
p. 904
|
artikel
|
Tijdschrift beschrijving